US68404V1008 - Common Stock
NASDAQ:OPTN (10/4/2022, 10:21:08 AM)+0.07 (+1.98%)
|GICS Sector||Health Care|
|Earnings (Last)||08-11 2022-08-11/bmo||Earnings (Next)||11-14 2022-11-14|
|Ins Owners||1.99%||Inst Owners||39.48%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 189 full-time employees. The company went IPO on 2017-10-13. The firm's first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), is a therapeutic utilizing the Company's Exhalation Delivery System (EDS), which delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps. The Onzetra Xsail is a sumatriptan nasal powder and sells in the United States, Canada and Mexico.
1020 Stony Hill Rd Ste 300
Yardley PENNSYLVANIA 19067
CEO: Peter K. Miller
ReOpen1 Phase 3 Clinical Trial Chosen as a Top-Rated Abstract in Clinical Rhinology...
Company reports second quarter XHANCE net revenue of $20.6 million increased 12% compared to second quarter 2021 Company plans to submit an sNDA for...
Conference Call and Webcast to be held August 11, 2022, at 8:00 a.m. Eastern Time...
XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trialsto reduce exacerbations for patients with chronic sinusitis ...
Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic...
First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients ...
Here you can normally see the latest stock twits on OPTN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.